drugset
drugset / Trial / NCT00592527

Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes

NCT00592527 ↗

Phase 3 Completed 132 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate the blood glucose achieved with insulin detemir as add-on to current oral antidiabetic drug (OAD) treatment in subjects with type 2 diabetes.

Timeline

Start
2004-04
Primary completion
2004-12
Completion
2004-12

Publications

  • Results Ramachandran A, Harish K, Sundaram A, Mayur P, Sunil GS, Srishyla MV. Improved Efficacy when Insulin Detemir is added to OADs in Indian Subjects with Type 2 Diabetes. Diabetes 2006; 55 (Suppl. 1): A469 (2028-PO)

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin detemir Protein / enzyme biologic — —

Indications

type 2 diabetes mellitus